Delcath Systems Inc (DCTH)vsEdwards Lifesciences Corp (EW)
DCTH
Delcath Systems Inc
$16.39
-0.06%
HEALTHCARE · Cap: $585.02M
EW
Edwards Lifesciences Corp
$89.95
-0.91%
HEALTHCARE · Cap: $52.33B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 6725% more annual revenue ($6.51B vs $95.42M). EW leads profitability with a 15.4% profit margin vs 0.6%. DCTH appears more attractively valued with a PEG of 1.60. EW earns a higher WallStSmart Score of 51/100 (C-).
DCTH
Hold41
out of 100
Grade: D
EW
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DCTH.
Margin of Safety
+69.0%
Fair Value
$255.88
Current Price
$89.95
$165.93 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 20.6% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Strong operational efficiency at 29.8%
Areas to Watch
Expensive relative to growth rate
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.4% — below average capital efficiency
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : DCTH
The strongest argument for DCTH centers on Debt/Equity, Revenue Growth. Revenue growth of 20.6% demonstrates continued momentum.
Bull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Market Cap. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bear Case : DCTH
The primary concerns for DCTH are PEG Ratio, EPS Growth, Market Cap. A P/E of 1686.0x leaves little room for execution misses. Thin 0.6% margins leave little buffer for downturns.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 54.0x leaves little room for execution misses.
Key Dynamics to Monitor
DCTH profiles as a growth stock while EW is a mature play — different risk/reward profiles.
EW carries more volatility with a beta of 0.85 — expect wider price swings.
DCTH is growing revenue faster at 20.6% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
EW scores higher overall (51/100 vs 41/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Delcath Systems Inc
HEALTHCARE · MEDICAL DEVICES · USA
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company is headquartered in New York, New York.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?